Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
Gail Torkildsen,1 Abhijit Narvekar,2 Mark Bergmann3 1Andover Eye Associates, Andover, MA, 2Alcon Research Ltd, Fort Worth, TX, 3Apex Eye, Cincinnati, OH, USA Background: Symptom relief for the duration of 24 hours after treatment would benefit patients with allergic conjunctivitis. Objective: To co...
Guardado en:
Autores principales: | , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7cd5332632fa45a4bb648507e0466e30 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|